Dr. Abidi Pharmaceutical Laboratories (DABID) financial ratios
Every ratio computed for this symbol, period by period, beside its industry and its own board
Fundamental analysis of DABID on Fundai: DABID Fundamental Analysis, Mehr 1405: Profit Forecast and Valuation
- Ticker
- DABID
- Industry
- Pharmaceuticals
- Market
- Tehran Stock Exchange
Latest periods
| Item | Report to 1404/09/30 | Report to 1403/09/30 | Report to 1402/09/30 | Report to 1401/09/30 |
|---|---|---|---|---|
| P/E TTM | 11.30 | 22.86 | 18.09 | 14.79 |
| P/S TTM | 3.72 | 5.19 | 5.77 | 5.07 |
| P/B | 5.02 | 7.08 | 8.02 | 7.51 |
| Gross margin TTM | 58.4% | 55.5% | 62.4% | 62.3% |
| Net margin TTM | 32.9% | 22.7% | 31.9% | 34.3% |
| ROA TTM | 22.8% | 14.6% | 18.7% | 23.7% |
| ROE TTM | 44.4% | 31.0% | 44.3% | 50.8% |
| Collection period TTM | 117 days | 108 days | 106 days | 92 days |
| Inventory period TTM | 266 days | 347 days | 405 days | 350 days |
| PEG TTM | 0.15 | 3.71 | 0.37 | 0.14 |
| PEGY TTM | 0.14 | 3.27 | 0.36 | 0.14 |